Outcomes significantly affected by depression and anxiety among patients with gout as identified using multivariable analyses.
| Outcome (Author, Yr) | Depression (95% CI) | Anxiety (95% CI) |
|---|---|---|
| HRQOL | ||
| SF-36 MCS (Fu, 201723) | β-14.27 (-22.09 to -6.45) | β -13.45 (-25.48 to -1.43) |
| SF-36 PCS (Fu, 2017) | β -16.65 (-23.93 to -9.37) | |
| SF-36 PCS (Chandratre, 201840) | β -1.98 (-2.24 to -1.71) | β -1.81 (-2.14 to -1.47) |
| GIS CO (Chandratre, 2018) | β 0.84 (0.50 to 1.19) | β 0.88 (0.50 to 1.26) |
| GIS MSE (Chandratre, 2018) | β 1.07 (0.72 to 1.42) | β 1.11 (0.72 to 1.50) |
| GIS UTN (Chandratre, 2018) | β 0.42 (0.16 to 0.69) | β 0.38 (0.08 to 0.68) |
| GIS WBDA (Chandratre, 2018) | β 1.47 (1.13 to 1.82) | β 1.44 (1.05 to 1.82) |
| GIS CDA (Chandratre, 2018) | β 1.47 (1.16 to 1.78) | β 1.70 (1.36 to 2.05) |
| Disability | ||
| HAQ-DI (Fu, 2017) | β 2.11 (3.57 to 19.23) | |
| HAQ-DI (Chandratre, 2018) | β 0.06 (0.05 to 0.07) | β 0.06 (0.05 to 0.07) |
| Comorbidities | ||
| Erectile dysfunction (Hsu, 201526) | aHR 2.01 (1.53 to 2.65) | aHR 1.50 (1.15 to 1.97) |
aHR: adjusted HR; GIS: Gout Impact Scale (CDA: concern during attack; CO: concern overall; MSE: medication side effects; UTN: unmet treatment need; WBDA: wellbeing during attack); HAQ-DI: Health Assessment Questionnaire-Disability Index; HRQOL: health-related quality of life; SF-36 MCS: 36-item Short Form survey, mental component summary; SF-36 PCS: 36-Item Short Form survey, Physical Component Score.